Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle(TM) nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation will focus on the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle(TM) platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications.
The companies plan to showcase development progress across multiple Deciparticle(TM) programs. These include Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI(TM) platform. This integration represents a significant step in leveraging AI to accelerate nanomedicine development.
This announcement is important because it addresses a critical challenge in oncology: the delivery of water-insoluble drugs. Many potent anticancer agents have poor solubility, limiting their clinical use. The Deciparticle platform's ability to form particles smaller than 20 nanometers could overcome this barrier, potentially improving therapeutic efficacy and reducing side effects. The move to present at BIO 2026, a major industry conference, signals the companies' confidence in the platform's maturity and potential impact.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products with high unmet medical needs. The company benefits from a robust portfolio of inventions by CEO Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, primarily in oncology. The collaboration between Oncotelic and Sapu Nano combines expertise in drug development and nanomedicine engineering.
For more information, the full press release is available at https://ibn.fm/RUG7m. The latest news and updates relating to OTLC are available at https://ibn.fm/OTLC.
